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ABSTRACT
Introduction: Intanza®/IDflu® (Sanofi Pasteur SA, 
Lyon, France), a split-virion, trivalent influenza 
vaccine delivered by intradermal injection with a 
microinjection system, became available in adults 
18-59 years of age (9 μg) and ≥60 years of age (15 μg) 
as of the 2010/2011 northern hemisphere 
influenza season. Methods: This study assessed 
the acceptability of intradermal vaccination 
with Intanza/IDflu in routine clinical practice 
in adult vaccinees and their vaccine prescribers. 
Vaccine prescribers and adults who had elected 
to be vaccinated with Intanza/IDflu during 
the 2010/2011 northern hemisphere influenza 
season were recruited to complete surveys about 
their opinions of influenza vaccination and 
their acceptance of the intradermal vaccination. 
Czech subjects 18-59 years of age were vaccinated 
with the 9 μg formulation and those ≥60 years of 
age with the 15 μg formulation of Intanza/IDflu. 
All Turkish subjects were vaccinated with the 
9 μg formulation, as Intanza/IDflu 15 μg was not 
available in Turkey at the time the survey was 
conducted. Results: One thousand and twelve 
vaccinees and 28 vaccine prescribers in the 
Czech Republic, and 249 vaccinees and 15 vaccine 
prescribers in Turkey completed questionnaires. 
Overall, 96.1% of vaccinees were satisfied or very 
satisfied with Intanza/IDflu. The main reason for 
satisfaction was that the injection was considered 
minimally painful. Most (93.9%) vaccinees 
reported that they would prefer to receive the 
same vaccination next year. Furthermore, 95.3% of 
vaccine prescribers were satisfied or very satisfied 
with the intradermal vaccine, and 82.6% preferred 
intradermal over intramuscular vaccination. 
Conclusions: Intradermal vaccination for seasonal 
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influenza using Intanza/IDflu is well accepted 
by adult vaccinees and vaccine prescribers. By 
providing an additional, well-accepted method, 
Intanza/IDflu might help increase seasonal 
influenza vaccination rates in adults.
Keywords: acceptability; influenza; Intanza/
IDflu; intradermal; seasonal; trivalent-
inactivated; vaccine; vaccinee satisfaction
INTRODUCTION 
Seasonal influenza is a threat to public 
health with a major socioeconomic impact.1
Worldwide, influenza is responsible for 
3-5 million cases of severe illness and 250,000-
500,000 deaths each year,2 most of which 
are in high-risk groups, including the elderly 
(≥65 years), children up to 5 years of age, 
pregnant women, and people with certain 
chronic diseases and conditions.2-6 Working-
age adults are at lower risk of complications, 
hospitalization, and death than high-risk groups, 
but they account for approximately one-third of 
the annual cost of seasonal influenza, mostly due 
to work absenteeism and reduced productivity.7,8
Vaccination is the most cost-effective medical 
intervention against seasonal influenza.9,10
The World Health Organization currently 
recommends that by 2014/15, influenza 
vaccination coverage should reach 75% in 
elderly adults and all persons with underlying 
diseases,11 targets officially adopted in 2009 
by the European Union.12 In the US, universal 
influenza vaccination has been recommended 
for all children ≥6 months of age since 2010.13
The influenza vaccine coverage, however, 
remains far below these targets. In European 
countries, influenza vaccine coverage during 
the 2006-2007 influenza season ranged 
from 2%-82% in adults over 65 years of age 
and from 28%-75% in clinical risk groups.14
In the US, the most recently reported seasonal 
influenza coverage rates were 28% in adults 
18-49 years of age not at risk, 36% in adults 18-49 
years of age at high risk (ie, with underlying 
conditions), 45% in adults 50-64 years of age, 
and 68% in adults 65 years of age and older.15
Seasonal influenza vaccines have been 
generally administered by intramuscular (i.m.) 
injection. Vaccination by the intradermal (i.d.) 
route using a microinjection system has been 
proposed as a way of improving influenza vaccine 
uptake because it uses a needle 10 times shorter 
than the i.m. needle, and because it allows 
rapid and safe vaccination.16 Intanza®/IDflu®
(Sanofi Pasteur SA, Lyon, France), the first 
microneedle, trivalent, inactivated influenza 
vaccine, is administered using the Soluvia™ 
microinjection system (Becton Dickinson, 
Franklin Lakes, NJ, USA), which consists of 
a prefilled 0.5 mL glass syringe fitted with 
a 30-gauge, short-bevel microneedle that 
protrudes 1.5 mm from a depth-limiting tip.17
The microinjection system also includes a shield 
that covers the needle after use, preventing 
needle reuse and accidental needle-stick injuries. 
Intanza/IDflu was approved in Europe in 2009 
by the European Medicines Agency for the 
prevention of influenza in both working-age 
adults (18-59 years of age; 9 μg hemagglutinin 
per strain) and elderly adults (≥60 years of age; 
15 μg hemagglutinin per strain).17,18 Clinical 
studies have shown that the 9 μg formulation of 
Intanza/IDflu has noninferior immunogenicity 
and that the 15 μg formulation has greater 
immunogenicity than Vaxigrip® (Sanofi Pasteur 
SA, Lyon, France), an i.m., split-virion, trivalent 
influenza vaccine that has been used for more 
than 45 years and has an established record of 
safety and efficacy.19-23 In addition, the systemic 
safety profile of both formulations of Intanza/
IDflu are similar to that of Vaxigrip. Local 
reactions are more common with Intanza/IDflu 
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than Vaxigrip, which is as expected because the 
injection site reactions occur in the skin rather 
than the muscle, where local reactions can be 
more easily observed.
Recommendations in Turkey are for 
influenza vaccination in people 65 years 
of age and older living in nursing homes 
or elderly care centers; in all patients with 
chronic pulmonary, cardiac, metabolic, or 
kidney diseases, hemoglobinopathies, immune 
deficiency, or receiving immunosuppressants; 
and in adolescents and children receiving chronic 
aminosalicylates.24 In the Czech Republic, 
recommendations are for influenza vaccination 
in people with chronic pulmonary disease, 
cardiovascular disease (except hypertension), or 
renal disease.25 In the current study, the authors 
assessed the acceptability of i.d. influenza 
vaccination with Intanza/IDflu in routine 
clinical use during the 2010/2011 northern 
hemisphere influenza season in Turkey and the 
Czech Republic, and examined vaccinee attitudes 
towards vaccination for seasonal influenza.
MATERIALS AND METHODS
Study Design and Participants
This was an uncontrolled, noninterventional, 
observational, multicenter study on the 
acceptance of Intanza/IDflu in routine clinical 
practice by adult subjects and healthcare 
practitioners. The survey was carried out in 
the Czech Republic between October 6 and 
November 10, 2010 and in Turkey between 
December 31, 2010 and January 31, 2011. 
The study was performed in accordance with 
local laws, rules, and regulations, including 
the Declaration of Helsinki, the guidelines 
of Good Pharmacoepidemiology Practices 
(Appendix 5), European Directive for Data 
Protection (95/46/EC), Volume 9A, and 
national pharmacovigilance regulations. 
Healthcare professionals at general practice 
and occupational health clinics in Turkey and 
the Czech Republic conducted the surveys. 
In the Czech Republic, an offer to participate 
in the study was extended to the Ministry 
of Defense, with most of the military public 
health physicians taking part. In addition, the 
study was offered to the Ministry of the Interior 
and to the Society of General Practitioners 
from which regional clinics participated. In 
Turkey, participating physicians were selected 
by Sanofi Pasteur through collaboration with 
a contract research organization. Selection 
of participating physicians was made on the 
basis of their potential patient populations. 
The participating clinics consecutively enrolled 
adults >18 years old (Czech Republic) or adults 
18-59 years old (Turkey) to be vaccinated 
with Intanza/IDflu and who were willing to 
complete surveys. No restrictions were made 
with respect to the urbanization, sex ratio, 
socioeconomic status, presence of chronic 
diseases, or other demographic factors. Each 
vaccinee was required to provide written 
informed consent to receive the vaccine and had 
to be vaccinated to be included in the survey. 
Exclusion criteria included hypersensitivity to 
the active substances or any of the excipients. 
Immunization was postponed in vaccinees with 
febrile illness or acute infection.
Treatments and Assessments
In the Czech Republic, subjects 18-59 years of 
age were vaccinated with Intanza/IDflu 9 μg 
and those ≥60 years of age were vaccinated 
with Intanza/IDflu 15 μg. All subjects in Turkey 
were vaccinated with Intanza/IDflu 9 μg. 
Immediately after vaccination, vaccinees 
completed a self-administered questionnaire 
that collected demographic information and 
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asked the subjects about their perception of 
the risk of getting influenza, their influenza 
vaccination history, their satisfaction with the 
i.d. vaccination, and their vaccine preference 
for the next year. Vaccinees were also contacted 
by telephone 8 days after vaccination and asked 
again about their vaccine preference for next 
year. At the end of the study, prescribers of the 
vaccine completed a questionnaire collecting 
demographic information and asking them 
about their satisfaction with Intanza/IDflu.
Statistical Analysis
All analyses were performed using SAS version 9.1 
(SAS Institute, Cary, NC, USA). Categorical 
variables were described by the percentage 
of each response choice, with missing data 
excluded in the calculation of percentage.
RESULTS
Intanza/IDflu Vaccinee Responses
A total of 1261 vaccinees completed the 
survey (Table 1). In the Czech Republic, 
the majority of vaccinees were men, whereas in 
Turkey, the majority of vaccinees were women. 
All 1012 vaccinees in the Czech Republic 
were vaccinated according to the protocol, 
whereas 14 of 249 in Turkey were above the 
age for enrollment (ie, ≥60 years of age, which 
constituted off-label use of Intanza/IDflu 9 μg) 
and, therefore, were not vaccinated according 
to the protocol. 
Risk Perception for Contracting Influenza
Most vaccinees in both countries felt at risk of 
contracting influenza. In the Czech Republic, 
66.7% of adults 18-59 years of age and 89.2% 
of elderly adults felt at risk, whilst in Turkey, 
90.3% felt at risk (Table 2). In Turkish and Czech 
adults 18-59 years of age, the most frequent 
reason for feeling at risk was “I come into 
contact with many people,” whereas in elderly 
Czech adults, the most common reason was “I 
have a chronic illness” followed by “I am at risk 
because of my elderly age.”
Only 10.8% of elderly vaccinees in the Czech 
Republic, 33.3% of Czech adults 18-59 years of 
age, and 9.7% of vaccinees in Turkey did not 
feel at risk of contracting influenza. For Turkish 
vaccinees and Czech vaccinees 18-59 years of 
age, the most common reason for not feeling 
at risk was “I rely on my natural defenses/
immunity system.” In Czech adults ≥60 years of 
age, the most common reason was “I have no 
chronic illness that puts me at risk of the flu.” 
Frequency of Vaccination
In the Czech Republic, most vaccinees reported 
being vaccinated for influenza every year 
(65.4% of adults 18-59 years of age and 79.6% of 
adults ≥60 years of age). Less than 20% reported 
that they had not been previously vaccinated 
(19.3% of adults 18-59 years of age and 12.6% 
of adults ≥60 years of age). Of those previously 
vaccinated, 83.1% of adults 18-59 years of 
age and 93.1% of adults ≥60 years of age had 
been vaccinated the year before. In contrast, 
more than half of vaccinees in Turkey (51.6%) 
reported that they had not been previously 
vaccinated for seasonal influenza (Table 2). 
In addition, just over half of those previously 
vaccinated (57.1%) had been vaccinated the 
year before.
Main Reasons for Being Vaccinated
In both Turkey and the Czech Republic, the 
most common reason prompting vaccination, 
cited by more than half of the vaccinees, was 
the advice of a physician (Table 2). In Czech 
vaccinees, the second-most common reason 
was “my own belief in the importance of flu 
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vaccination” (41.7% of adults 18-59 years of 
age and 31.1% of adults ≥60 years of age), but 
this reason was cited by only 6.6% of Turkish 
vaccinees. Instead, the advice of a physician’s 
office assistant or nurse was the second-most 
common prompting vaccination in Turkey.
Main Reasons for Missing Vaccination
In Turkey, the most common reason for 
missing previous vaccinations was “I was not 
encouraged to be vaccinated” (Table 2), whereas 
in the Czech Republic, not being encouraged 
to be vaccinated was reported as the reason for 
missing vaccinations by only 3.8% of adults 
18-59 years of age and only 23.3% of adults 
≥60 years of age. Instead, the most common 
reason for missing previous vaccinations was 
“I did not feel that I was at risk of catching 
the flu.” 
Vaccinees’ Opinions of the Most Effective 
Reminder to be Vaccinated 
In both countries, more than two-thirds of 
vaccinees indicated that advice of their physician 
or general practitioner (GP) would be the most 
effective reminder to be vaccinated (Table 2). 
A postcard, email, or text message sent by the nurse, 
physician’s assistant, or physician’s/GP’s clinic was 
cited as the second most effective reminder. 
Vaccinee Satisfaction with Intanza/IDflu
Overall, 96.1% of vaccinees reported being 
satisfied or very satisfied with Intanza/IDflu 
(Table 2). This included 96.0% of vaccinees 
in Turkey, and in the Czech Republic, 95.6% 
of vaccinees 18-59 years of age and 98.8% of 
vaccinees ≥60 years of age. Of respondents 
vaccinated every year for influenza (and, 
therefore, previously vaccinated i.m.), 90.9% 
(60/66) in Turkey and 98.0% (672/686) in the 
Czech Republic were satisfied or very satisfied. 
Of those not previously vaccinated, 96.8% 
(122/126) in Turkey and 93.5% (172/184) 
in the Czech Republic were satisfied or very 
satisfied. The main reason for satisfaction in 
both countries was “the injection was minimally 
painful/only hurt a little,” followed by “the 
vaccination/administration process was quick.” 
According to multivariate statistical analysis, in 
both countries, satisfaction with Intanza/IDflu 
Table 1. Demographics.
Czech Republic Turkey
Intanza/IDflu 9 μg Intanza/IDflu 15  μg Intanza/IDflu 9  μg
n % n % n %
Age (years) n=845 n=167 n=249
18-49 693 82.0 0 0.0 144 57.8
50-59 152 18.0 0 0.0 91 36.5
60-74 0 0.0 120 71.9 9* 3.6
≥75 0 0.0 47 28.1 5* 2.0
Sex n=845 n=165 n=249
Male 677 80.1 88 53.3 102 41.0
Female 168 19.9 77 46.7 147 59.0
*Off-label use.
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Table 2. Vaccinee responses (continued on next page).
Czech Republic







n % n % n %
Do you feel at risk of catching the flu? n=248 n=845 n=167
Yes 224 90.3 564 66.7 149 89.2
No 24 9.7 281 33.3 18 10.8
Reason for feeling at risk n=216 n=563 n=148
I have a chronic illness 34 15.7 49 8.7 70 47.3
I am at risk because of my elderly age 11 5.1 8 1.4 45 30.4
I come into contact with many people 146 67.6 443 78.7 27 18.2
I previously had the flu 25 11.6 63 11.2 6 4.1
Reason for not feeling at risk n=22 n=281 n=17
I have no chronic illness that puts me at risk of the flu 5 22.7 88 31.3 8 47.1
I am too young to be at risk 3 13.6 15 5.3 0 0.0
I try to avoid crowded places/environments 5 22.7 10 3.6 4 23.5
I rely on my natural defenses/immunity system 7 31.8 119 42.3 3 17.6
I have a healthy lifestyle 2 9.1 49 17.4 2 11.8
Who/what prompted you to receive your flu vaccination today? n=243 n=845 n=167
Advice of physician or GP 160 65.8 425 50.3 96 57.5
Advice of physician’s office assistant or nurse 51 21.0 11 1.3 7 4.2
Advice of pharmacist 0 0.0 6 0.7 0 0.0
Advice of family, friend, or colleague 16 6.6 48 5.7 10 6.0
My own belief in the importance of flu vaccination 16 6.6 352 41.7 52 31.1
Poster or communication in the waiting room or pharmacy 0 0.0 3 0.4 2 1.2
How often do you receive a flu vaccine? n=244 n=844 n=167
Every year 66 27.0 552 65.4 133 79.6
Every 2 years 22 9.0 47 5.6 4 2.4
Less than every 2 years 30 12.3 82 9.7 9 5.4
Have not in the past – this is my first time 126 51.6 163 19.3 21 12.6
When did you last receive a flu vaccine? n=119 n=681 n=145
Last year 68 57.1 566 83.1 135 93.1
Two years ago 22 18.5 55 8.1 5 3.4
Several years ago 15 12.6 50 7.3 3 2.1
I don’t remember 14 11.8 10 1.5 2 1.4
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Table 2 (continued). Vaccinee responses.
Main reason for missing flu vaccination last year or the year before n=176 n=289 n=30
I was not encouraged to be vaccinated 97 55.1 11 3.8 7 23.3
I have a fear of injections or needles 20 11.4 9 3.1 5 16.7
I was afraid of side effects or contracting flu from the vaccine 27 15.3 58 20.1 4 13.3
I did not feel that I was at risk of catching the flu 32 18.2 211 73.0 14 46.7
Which of the following would be most effective in reminding 
you of future flu vaccination?
n=243 n=845 n=167
Advice from physician or GP 192 79.0 546 64.6 114 68.3
Postcard, email, SMS sent by the nurse, physician’s assistant, 
or physician’s/GP’s clinic
30 12.3 117 13.8 23 13.8
Reminder from a pharmacist 1 0.4 7 0.8 1 0.6
Advice or reminder from family or a friend 7 2.9 42 5.0 7 4.2
Articles in the media 7 2.9 37 4.4 15 9.0
None 6 2.5 96 11.4 7 4.2
How satisfied are you with the vaccine you received today? n=249 n=845 n=167
Very satisfied 167 67.1 404 47.8 121 72.5
Satisfied 72 28.9 404 47.8 44 26.3
Somewhat satisfied 9 3.6 22 2.6 2 1.2
Not satisfied 1 0.4 15 1.8 0 0.0
What was the main reason for your satisfaction? n=231 n=825 n=166
The injection was minimally painful/only hurt a little 137 59.3 468 56.7 118 71.1
I was reassured by the microneedle (short and thin needle) 56 24.2 37 4.5 10 6.0
The vaccination/administration process was quick 38 16.5 320 38.8 38 22.9
Other 1 0.4 2 0.2 0 0.0
For next year’s flu, would you consider the following?  
(day of vaccination)
n=245 n=844 n=167
To be vaccinated with the same vaccine as today 241 98.4 774 91.7 164 98.2
To be vaccinated with the intramuscular vaccine 4 1.6 23 2.7 3 1.8
No vaccination 0 0.0 47 5.6 0 0.0
For next year’s flu, would you consider the following?  
(8 days after vaccination)
n=249 n=844 n=166
To be vaccinated with the same vaccine as today 233 93.6 723 85.7 161 97.0
To be vaccinated with the intramuscular vaccine 13 5.2 57 6.8 4 2.4
No vaccination 3 1.2 64 7.6 1 0.6
GP=general practitioner.
Results were from a self-administered questionnaire. Percentages were calculated as 100 × (number in each category  
[n] ÷ the number of responses available for each question [n]).
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and preference of i.d. versus i.m. vaccination 
were not significantly influenced by age, sex, 
or the feeling of being at risk for being infected 
with influenza (data not shown). 
When asked immediately after vaccination, 
98.4% of Turkish vaccinees, 98.2% of elderly 
Czech adults, and 91.7% of Czech adults 
18-59 years of age indicated that they would 
like “to be vaccinated with the same vaccine 
as today” (Table 2). When asked again 8 days 
after vaccination, 93.6% of Turkish vaccinees, 
85.7% of Czech adults 18-59 years of age, 
and 97.0% of Czech adults ≥ 60 years of age 
indicated that they would like to receive the 
same vaccine next year. Overall, the 93.9% 
preferred the same vaccine next year when 
asked immediately and 88.7% when asked 
again 8 days later.
Prescriber Responses
A total of 46 vaccine prescribers answered 
questionnaires, including 18 in Turkey and 
28 in the Czech Republic. Most prescribers (n=11) 
in Turkey were specialists, and all practiced in 
urban settings (>500 inhabitants/km2). In the 
Czech Republic, most vaccine prescribers (n=24) 
were GPs, and 75% of prescribers practiced 
in urban settings, 11% in peri-urban settings 
(100-500 inhabitants/km2), and 14% in rural 
areas (<100 inhabitants/km2).
Prescriber Satisfaction with Intanza/IDflu
In Turkey, 100% of prescribers were satisfied 
or very satisfied with Intanza/IDflu, and all 
preferred i.d. over i.m. vaccine (Table 3). In the 
Czech Republic, 92.8% were satisfied or very 
satisfied with Intanza/IDflu, and 71.4% preferred 
i.d. over i.m. vaccine. Overall, 95.3% were 
satisfied or very satisfied, and 82.6% preferred 
i.d. over i.m. vaccine.
DISCUSSION
This survey evaluated the acceptance 
in routine clinical practice of the first 
microneedle influenza vaccine, Intanza/
IDflu, by adult vaccinees and their vaccine 
prescribers during the 2010/2011 northern 
hemisphere influenza season. The study, 
Table 3. Prescriber responses.
Turkey Czech Republic
n % n %
How satisfied are you with the i.d. vaccine? n=15 n=28
Very satisfied 5 33.3 17 60.7
Satisfied 10 66.7 9 32.1
Somewhat satisfied 0 0.0 2 7.1
Not satisfied 0 0.0 0 0.0
Do you prefer i.d. over i.m. vaccine? n=18 n=28
Yes 18 100.0 20 71.4
No 0 0.0 8 28.6
i.d.=intradermal; i.m.=intramuscular.
Results were from a self-administered questionnaire. Percentages were calculated as 100 × (number in each category  
[n] ÷ the number of responses available for each question [n]).
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which included 1261 vaccinees  and 
46 vaccine prescribers in the Czech Republic 
and Turkey, showed a high rate of acceptance 
of i.d. vaccination with Intanza/IDflu by both 
vaccinees and vaccine prescribers.
Overall, 96.1% of vaccinees reported 
being satisfied or very satisfied with Intanza/
IDflu, with similar rates in Turkey and the 
Czech Republic, and irrespective of age. Also, 
overall, 93.9% said they would prefer the same 
vaccination (i.d.) when asked immediately after 
vaccination, and 88.7% responded that they 
would prefer the same vaccine when asked again 
8 days later. This suggests that any reactivity 
during the week following the vaccination 
had little effect on vaccine acceptability. In 
addition, more than 90% of those vaccinated 
every year were satisfied or very satisfied with 
Intanza/IDflu, indicating that satisfaction rates 
for Intanza/IDflu were high even in subjects 
previously having received i.m. vaccination.
Similar results were found in a 2010 survey 
of adult vaccinees 18-59 years of age in 
Australia and Argentina, with 98% reporting 
being satisfied or very satisfied with Intanza/
IDflu 9 μg.26 Similarly, a survey of vaccinees 
in two phase 3 studies of Intanza/IDflu found 
that 96% of vaccinees were satisfied with the 
injection, and more than 96% considered the 
injection to be very or totally acceptable.27
Also, similar to the current survey, 87% of 
vaccinees in Argentina reported a preference 
for receiving the same injection the following 
year when asked immediately after the 
vaccination, and 86% when asked again after 
7-10 days.26 Collectively, the previous and 
current surveys show that vaccinee satisfaction 
is high for Intanza/IDflu, regardless of the 
country or age group.
In both Turkey and the Czech Republic, 
minimal pain of injection was the main reason 
for satisfaction reported by vaccinees. This 
was the same main reason for satisfaction in 
the Australia/Argentina survey.26 In contrast, a 
recent survey of the general public in France and 
Germany following an online presentation of 
Intanza/IDflu (and in the absence of vaccination) 
found that the thin, short needle is perceived 
as the most important benefit, and less pain 
or pain-free administration is the fourth most 
important benefit.28 Being reassured by the short 
and thin microneedle was the second (Turkey) 
or third most (Czech Republic) common reason 
for satisfaction in the current survey. Clearly, 
there are differences in the perceived benefits 
of Intanza/IDflu according to whether or not 
those participating in the surveys had received 
the injection, and different reasons motivating 
individuals to select i.d. vaccination with Intanza/
IDflu for the first time and subsequent times. 
Professional opinion in favor of i.d. influenza 
vaccination with Intanza/IDflu was high, 
according to this survey. In Turkey, all prescribers 
indicated that they were satisfied or very 
satisfied with Intanza/IDflu, and all preferred 
i.d. over i.m. vaccination. In the Czech Republic, 
more than 90% were satisfied or very satisfied 
with Intanza/IDflu, and approximately three-
quarters preferred i.d. over i.m. vaccination. 
These results agree well with those from the 
previous Australia/Argentina survey, where 85% 
were satisfied or very satisfied with Intanza/IDflu 
and 74% preferred i.d. over i.m. vaccination.26
Although satisfaction with Intanza/
IDflu was high in both Turkey and the 
Czech Republic, the attitudes about seasonal 
influenza differed between the countries and 
between age groups. Only approximately 
10% of vaccinees in Turkey (most of whom 
were 18-59 years old) and vaccinees 60 
years or older in the Czech Republic felt 
that they were not at risk of catching the 
flu. In contrast, approximately 33% of the 
18-59-year age group in the Czech Republic 
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did not feel at risk. Although this suggests that 
feelings of risk of catching the flu might be 
similar in elderly adults in the Czech Republic 
and the vaccinees in Turkey, reasons for feeling 
or not feeling at risk differed. For example, 
coming into contact with many people was 
the most common reason for feeling at risk in 
Turkey and in vaccinees 18-59 years of age in the 
Czech Republic, whereas having a chronic illness 
was the most common reason in elderly Czech 
adults. Furthermore, relying on natural defenses 
was the most common reason for not feeling at 
risk in Turkey and in vaccinees 18-59 years of 
age in the Czech Republic, whereas not having a 
chronic illness was the most common reason in 
elderly Czech adults. In other words, for elderly 
Czech adults, whether they had a chronic illness 
was the main factor influencing whether they 
were vaccinated for influenza, whereas other 
factors were more important for younger Czech 
adults and for the vaccinees in Turkey.
In the Czech Republic, approximately two-
thirds of vaccinees 18-59 years old and 80% 
of elderly respondents reported receiving the 
influenza vaccination every year, and more than 
80% in both young adults and elderly respondents 
reported having been vaccinated for influenza 
the previous year. These coverage rates are much 
higher than in Turkey, where only 27.0% reported 
being vaccinated every year and only 57.1% 
reported being vaccinated the year before. For 
the vaccinees in the Czech Republic that missed 
recent vaccinations, the most common reason 
was that they did not feel at risk of catching the 
flu, and in Turkey, the most common reason 
for missing recent vaccinations was not being 
encouraged to be vaccinated. Importantly, for all 
vaccinees, advice of the physician or a GP was 
considered the most effective reminder to receive 
the influenza vaccination. A postcard, email, or 
text message sent by the physician’s office or 
clinic was considered the second most effective 
reminder. This agrees with the conclusions of 
the previous survey in Argentina and Australia.26
Therefore, educational efforts should probably 
focus on encouraging physicians to discuss 
seasonal influenza vaccination with their patients 
and to remind them to be vaccinated before the 
influenza season.
As in the Australia/Argentina survey,26 the 
results of this survey need to be interpreted in 
light of specific aspects of the study design and 
vaccinee profile. In particular, only subjects 
electing to receive i.d. vaccination with 
Intanza/IDflu were included in the survey, 
so the authors could not directly compare 
the acceptability of i.m. and i.d. influenza 
vaccination. Including only those electing 
to receive i.d. vaccination might also have 
biased the results in favor of i.d. vaccination. 
However, the results were nearly the same as 
determined in phase 3 clinical trials that also 
assessed satisfaction with Intanza/IDflu.27
Also, although the authors assessed vaccinee 
satisfaction immediately and 8 days after 
vaccination, reactivity was not assessed, so 
the impact of reactivity on satisfaction could 
not be directly determined. Finally, 14 of the 
249 vaccinees in Turkey were ≥60 years of age 
and were vaccinated with Intanza/IDflu 9 μg. 
However, these vaccinees represent only 6.4% 
of the total in the Turkish survey, so this should 
not substantially affect the conclusions.
In conclusion, collectively, these data and the 
authors’ previous results26 show that Intanza/
IDflu is well accepted by vaccinees and vaccine 
prescribers in routine clinical practice. Intanza/
IDflu might have the additional benefit of 
increasing vaccination rates in adults against 
seasonal influenza by offering an alternative 
vaccine with a smaller needle, as well as a 
minimally painful injection. Future studies are 
needed to assess the impact of Intanza/IDflu on 
influenza vaccination rates.
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